$209.90 general Payment -- Eli Lilly and Company to Dr. Robert Johnson
Eli Lilly and Company compensates Endocrinologist Robert Johnson for services rendered.
This page provides a detailed analysis of a $209.90 general payment from Eli Lilly and Company to Dr. Robert Johnson. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $209.90 |
| Payment Type | general |
| Payment Nature | Compensation for services other than consulting |
| Pharmaceutical Company | Eli Lilly and Company |
| Physician | Dr. Robert Johnson |
| NPI Number | 1552618969 |
| Physician Specialty | Endocrinology |
| Location | Trenton, NJ |
| Date of Payment | 2024-06-22 |
| Conflict Assessment | Low -- Routine |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Eli Lilly and Company made a $209.90 general payment to Robert Johnson, a Endocrinology specialist in Trenton, NJ. The payment of $209.90 to Dr. Robert Johnson by Eli Lilly and Company on June 22, 2024, was for services other than consulting. This payment falls under the 'general' payment type, indicating a broad category of compensation. The payment was made to an endocrinologist in Trenton, NJ, with NPI 1552618969.
Patient Guidance: What This Payment Means for You
This information relates to payments made to healthcare providers by pharmaceutical companies. It is important to understand the nature of these payments to ensure transparency in healthcare. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Payments for services other than consulting are common in the pharmaceutical industry, but the specific amount and nature should be evaluated within the context of the physician's specialty and services provided.
Regulatory Context: Sunshine Act Requirements
This record is part of the CMS Open Payments program, which aims to increase transparency regarding financial relationships between the healthcare industry and physicians.
Related Topics
This payment is related to the following healthcare transparency topics:
- pharmaceutical-payments
- physician-compensation
- cms-open-payments
- eli-lilly-and-company
- endocrinology
- medical-services
Understanding general Payments
general payments are one of several categories of financial transfers from pharmaceutical and medical device companies to physicians that must be reported under the Sunshine Act. Understanding the type and context of a payment is important for evaluating its significance. Not all payments are equal -- a research grant has very different implications than a promotional speaking fee.
Frequently Asked Questions About This Payment
What was this $209.90 payment for?
This was a general payment of $209.90 from Eli Lilly and Company to Robert Johnson, categorized as "Compensation for services other than consulting". The payment was reported under the Sunshine Act (CMS Open Payments).
Does Robert Johnson accept pharmaceutical money?
Yes, Robert Johnson received this $209.90 payment from Eli Lilly and Company. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Robert Johnson's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this general payment?
A general payment of $209.90 should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Endocrinology?
To compare this payment against Endocrinology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Endocrinology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Robert Johnson's relationship with Eli Lilly and Company?
The payment amount is relatively small ($209.90). This $209.90 general payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Endocrinology?
The payment nature specifies 'Compensation for services other than consulting'.
What should patients do after learning about this payment?
This information relates to payments made to healthcare providers by pharmaceutical companies. It is important to understand the nature of these payments to ensure transparency in healthcare.
What else should I know about this general payment?
The payment was made by a major pharmaceutical company, Eli Lilly and Company.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.